Board of Directors

Ricardo Moro-Vidal, M.D. is the CEO of BioCurex Inc. He is a founder of the company and has been an officer and director since March 2001.  Since 1996, Dr. Moro-Vidal has been the President of PBRC, formerly named Curex Technologies Inc., where he developed the RECAF cancer marker concept.  From 1980 to 1985, Dr. Moro-Vidal worked in cancer research at the French National Cancer Institute near Paris, France.  From late 1985 to 1988, he worked at the University of Alberta, Edmonton on onco-developmental biology.  From 1989 to 1996, he was engaged in various entrepreneurial ventures relating to diagnostics and medical instrumentation.  Dr. Moro-Vidal received his medical degree from the University of the Republic of Uruguay in 1979.

Denis R. Burger, Ph.D. is BioCurex's Chairman of the Board.  Prior to joining the Company, he had been Managing Director of Sovereign Ventures, LLC, a biotech investment and consulting firm.  He was Chairman and CEO of AVI BioPharma, Inc., a drug development company using gene targeted therapeutics, from 1997 to 2007 and founding Chairman of Epitope, Inc., a developer of diagnostic products, from 1981 to 1990.  He is currently a director of Trinity Biotech PLC, a diagnostic products developer, and Lorus Therapeutics, a cancer therapeutics company.  Earlier in his career, he was a Professor of Microbiology and Immunology, an Associate Professor of Surgery and the Director of the Histocompatibility Testing Laboratory at Oregon Health Sciences University.  He holds a B.A. degree in Bacteriology and Immunology from the University of California at Berkeley, and an M.S. and Ph.D. in Microbiology and Immunology from the University of Arizona, Tucson.

Paul D. Slowey, Ph.D. Is the President of BioCurex Inc. Dr. Slowey has been President and CEO of Oasis Diagnostics Corporation since 2007 and Managing Member of Bamburgh Marrsh LLC since 2002. Previously he held various diagnostic positions including; Director of International Sales for OraSure (formerly Epitope), Chief Operating Officer for Saliva Diagnostics, Director of International Sales for Incstar Corp. [now DiaSorin]. He holds a B.S. (Honors) from Sheffield Polytechnic (England), a Ph.D. in Organic Chemistry from the University of Newcastle-Upon-Tyne (England) and Post-Doctoral Fellowships from University of Victoria and Memorial University of Newfoundland (Canada).

Phil Gold, C.C., O.Q., M.D., Ph.D. has been a director since March 2001.  He has been employed by McGill University and/or its affiliate, Montreal General Hospital, in one or more capacities since 1968.  Currently, he is the Douglas G. Cameron Professor of Medicine, and Professor of Physiology and Oncology, at McGill University and the Executive Director of the Clinical Research Centre of the McGill University Health Centre. In the past he has served as Chairman of the Department of Medicine at McGill and Physician-in-Chief at the Montreal General Hospital. From 1978 to 1980, Dr. Gold was Director of the McGill Cancer Centre in Montreal, Quebec.  From 1980 to 1984, he was Physician-in-Chief of the Montreal General Hospital.  From 1985 to 1990, he served as Chairman of the Department of Medicine at McGill University in Montreal.  Dr. Gold’s early research led to the discovery and definition of the Carcinoembryonic Antigen (CEA), the blood test most frequently used in the diagnosis and management of patients with cancer. 

He has been elected to numerous prestigious organizations and has been the recipient of such outstanding awards as the Gairdner Foundation Annual International Award, the Isaak Walton Killam Award in Medicine of the Canada Council, the National Cancer Institute of Canada R.M. Taylor Medal, the Heath Medal of the MD Anderson Hospital, the Inaugural Ernest C. Manning Foundation Award, the Johann-Georg-Zimmerman Prize for Cancer Research, Medizinische Hochschule, Germany, the ISOBM Abbott Award (Japan), the Award of the Academy of International Dental Studies, and the Queen Elizabeth II Jubilee Medal. He has been elected to membership in the Royal Society of Canada, the American Society for Clinical Investigation, the Association of American Physicians, and Mastership in the American College of Physicians.  His contributions to teaching have been recognized by an award as a Teacher of Distinction from his Faculty of Medicine. He has been honored by his country, his province, his city and his university by appointment as a Companion of the Order of Canada, an Officer of l’Ordre National du Québec, a Member of the Academy of Great Montrealers; and a recipient of the Gold Medal of the McGill University Graduate Society, respectively. He has been the Sir Arthur Sims Traveling Professor to the British Commonwealth, and has served as a member of the Executive, and Chair of the Burroughs Wellcome Fund.  In 2006, the Phil Gold Chair in Medicine was inaugurated at McGill University and the first incumbent was selected in 2009.  Dr. Gold received a B. Sc. in 1957 and a M.Sc. in 1961 in Physiology from McGill University.  He received his MDCM in 1961 and his Ph.D. in 1965 from McGill University as well.

Jim Walsh, Ph.D. was appointed a director in September 2009.  Dr. Walsh has been the Chief Executive Officer of Biosensia Ltd., a point of care diagnostics  company since 2008 and interim Chief Executive Officer of Stokes Bio Ltd., a company specializing in the area of molecular diagnostics, since 2006.  Dr. Walsh has also been a non-executive director of Trinity Biotech Plc (“NASDAQ: TRIB”), an Irish diagnostics company since 1996 and a non-executive director of PuriCore Plc. (“LSE: PURI”), a U.S.-based healthcare company, since 2006.  Dr. Walsh has also been investment advisor to Bank of Ireland Kernel Capital Partners since 2007.  From 1990 to 1995, Dr. Walsh was Managing Director of Cambridge Diagnostics Ltd., a wholly owned subsidiary of Inverness Medical Innovations Inc. (“AMEX: IMA”).  From 1988 to 1990, Dr. Walsh worked with Fleming GmbH as R&D Manager.  Dr. Walsh is a graduate of the National University of Ireland and holds a Doctorate in Inorganic Chemistry and Post Doctorate qualifications in Immunochemistry.

Antonia Bold-de-Haughton, Antonia joined the Company in January 2000 as Corporate Administrator and in October 2009, was elected to the Board in the role of Corporate Secretary. Ms. Bold-de-Haughton has over 20 years senior management, governance and finance experience with particular focus in compliance with federal securities laws and stock exchange requirements. She has previously served as Chief Financial Officer of both public and private companies. She is a member of the Society of Corporate Secretaries.

Trent Davis, Mr. Davis has been with Paulson Investment Company, Inc. (Paulson) since 1991, and has served as Paulson Investment's President and CEO since 2005. Prior to being appointed as President and CEO, Mr. Davis served as Senior Vice President of Paulson's Syndicate Department. Mr. Davis is credited with bolstering the firm's Syndicate Department, overseeing the syndication of over 50 public and private offerings and raising approximately $600 million. Mr. Davis served as a board member and Chairman of the National Investment Banking Association. Mr. Davis holds a B.S. in Business and Economics from Linfield College, and has earned a Master's Degree in Business Administration from the University of Portland.